Codexis Launches Public Stock Offering, Dilution Risk Looms
CDXS sits 68% above its 52-week low of $0.958.
Summary
Codexis announced an underwritten public offering of common stock after market close on July 23. The size and pricing are not yet disclosed, but the company intends to use proceeds for working capital and general corporate purposes. With a market cap around $180 million and a stock price of $1.61, any meaningful raise will be dilutive. The offering follows a Q1 2026 report that showed revenue more than doubled and net loss narrowed, driven by a licensing agreement. The capital raise suggests the company needs additional funding despite improved results. The offering is subject to market conditions, and the final terms will determine the extent of dilution.
At the time of this announcement, CDXS was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $180.9M. The 52-week trading range was $0.96 to $3.87. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.